Table 5.
Association of CYP4F2, APOE and CYP2A6 SNPs with warfarin responsiveness during the initiation phase of therapy of 212 cardiovascular patients treated with warfarin
| Gene | SNP ID | Genotype | Poor respondersa | Good respondersb | Ultra respondersc | Overall P-value* |
|---|---|---|---|---|---|---|
| CYP4F2 | rs2108622 | CC | (17/93) 18.3% | (72/93) 77.4% | (4/93) 4.3% | 0.54 |
| P-value* | 1 | 0.95 | 0.88 | |||
| CT | (17/90) 18.9% | (66/90) 73.3% | (7/90) 7.8% | |||
| P-value* | 0.99 | 0.66 | 0.34 | |||
| TT | (5/29) 17.2% | (24/29) 82.8% | (0/29) 0.0% | |||
| P-value* | 0.99 | 0.69 | 0.40 | |||
| APOE | rs7412 | CC | (34/187) 18.2% | (143/187) 76.5% | (10/187) 5.3% | 0.25 |
| P-value* | 0.76 | 0.99 | 0.57 | |||
| TC | (4/19) 21.1% | (15/19) 78.9% | (0/19) 0.0% | |||
| P-value* | 0.97 | 0.96 | 0.59 | |||
| TT | (1/1) 100% | (0/1) 0.0% | (0/1) 0.0% | |||
| P-value* | 0.11 | 0.20 | 0.98 | |||
| APOE | rs405509 | GG | (14/67) 20.9% | (51/67) 76.1% | (2/67) 3% | 0.55 |
| P-value* | 0.81 | 1 | 0.62 | |||
| GT | (16/92) 17.4% | (72/92) 78.3% | (4/92) 4.3% | |||
| P-value* | 0.95 | 0.86 | 0.89 | |||
| TT | (9/53) 17% | (39/53) 73.6% | (5/53) 9.4% | |||
| P-value* | 0.96 | 0.86 | 0.27 | |||
| CYP2A6 | rs1801272 | AA | (37/207) 17.9% | (159/207) 76.8% | (11/207) 5.3% | 0.42 |
| P-value* | 0.45 | 0.68 | 0.87 | |||
| TA | (2/5) 40% | (3/5) 60% | (0/5) 0% | |||
| P-value* | 0.45 | 0.68 | 0.87 |
*Chi-Square Test with p value < 0.05 is considered significant.
a Poor responders (INR value below target).
b Good responders who have an INR value in the target range (therapeutic range).
c Ultra responders (INR over target).